TAK Stock Analysis: Buy, Sell, or Hold?
TAK - Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
$18.15
-0.03 (-0.15%)
▼
5d:
+4.44%
30d:
+5.29%
90d:
+11.71%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Get Alerted When TAK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: TAK shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: TAK shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$36.99
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$22.97
21.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 0.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TAK is currently trading at $18.15, which is considered extended relative to its 30-day fair value range of $16.74 to $17.76. The stock's valuation (Forward PE: 0.2) is in line with its historical norms (0.2). At these levels, the market is pricing in 2.8% annual earnings growth.
Technical Outlook: Technically, TAK is showing sideways momentum. The price is approaching resistance at $18.50. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TAK scores 17/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.94 (+19.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TAK is showing sideways momentum. The price is approaching resistance at $18.50. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TAK scores 17/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.94 (+19.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$16.74 -
$17.76
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
29.5%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (17/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($21.94)
- BULLISH: Expecting earnings turnaround to 2.8% growth with 10.2% revenue growth
- WARNING: Composite score 37/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$16.74 -
$17.76
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$17.28
Resistance Level
$18.50
Current Trend
Sideways
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
0.19
Wall Street Target
$21.94
(+19.6%)
Revenue Growth (YoY)
10.2%
Earnings Growth (YoY)
-9.8%
Profit Margin
-3.5%
Valuation Premium vs History
+2.8% premium
PE vs Historical
0.2 vs 0.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.8%
(market-implied from PE analysis)
1-Year Target
$18.85
(+3%)
2-Year Target
$19.38
(+6%)
3-Year Target
$19.92
(+9%)
3-Yr Target (if PE normalizes)
(PE: 0→0)
$20.64
(+13%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 93.0%)
$6433.72
(+34980%)
Base:
(SPY PE: 0.2, Growth: 93.0%)
$61.90
(+238%)
Bear:
(PE: 0.2, Growth: 93.0%)
$52.61
(+187%)
Share & Embed Analysis
Last updated: August 24, 2026 10:46 AM ET
Data refreshes hourly during market hours. Next update: 11:46 AM
Data refreshes hourly during market hours. Next update: 11:46 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TAK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 56 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 43 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 48 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 55 HOLD |
